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Familial hypertrophic cardiomyopathy (FHC) is the most frequent inherited cardiac disease.
It has been related to numerous mutations in many sarcomeric and even some
non-sarcomeric proteins. So far, however, no common mechanism has been identified by
which the many different mutations in different sarcomeric and non-sarcomeric proteins
trigger development of the FHC phenotype. Here we show for different MYH7 mutations
variance in force pCa-relations from normal to highly abnormal as a feature common to
all mutations we studied, while direct functional effects of the different FHC-mutations,
e.g., on force generation, ATPase or calcium sensitivity of the contractile system, can be
quite different. The functional variation among individual M. soleus fibers of FHC-patients
is accompanied by large variation in mutant vs. wildtype β-MyHC-mRNA. Preliminary
results show a similar variation in mutant vs. wildtype β-MyHC-mRNA among individual
cardiomyocytes. We discuss our previously proposed concept as to how different
mutations in the β-MyHC and possibly other sarcomeric and non-sarcomeric proteins may
initiate an FHC-phenotype by functional variation among individual cardiomyocytes that
results in structural distortions within the myocardium, leading to cellular and myofibrillar
disarray. In addition, distortions can activate stretch-sensitive signaling in cardiomyocytes
and non-myocyte cells which is known to induce cardiac remodeling with interstitial
fibrosis and hypertrophy. Such a mechanism will have major implications for therapeutic
strategies to prevent FHC-development, e.g., by reducing functional imbalances among
individual cardiomyocytes or by inhibition of their triggering of signaling paths initiating
remodeling. Targeting increased or decreased contractile function would require selective
targeting of mutant or wildtype protein to reduce functional imbalances.
Keywords: MYH7 -mutations, allelic imbalance, myocyte disarray, interstitial fibrosis, converter domain of myosin
head, myosin head stiffness, calcium sensitivity of muscle fibers, calcium sensitivity of cardiomyocytes
INTRODUCTION
Familial hypertrophic cardiomyopathy (FHC) is themost frequent
inherited cardiac disease and the most common cause of sudden
cardiac death in otherwise healthy young individuals and athletes
(Maron et al., 2003). FHC is characterized by asymmetric hyper-
trophy of the left ventricle, pronounced myocyte and myofibrillar
disarray, and interstitial fibrosis. These structural features together
with arrhythmias, unexplained syncopes and sudden cardiac death
are hallmarks of the FHC. The clinical phenotype of FHC is het-
erogeneous ranging from almost asymptomatic to highly malig-
nant with sudden cardiac death or development of end-stage
heart failure (Spirito et al., 1987; Maron et al., 2003). More than
300 FHC-related mutations were identified within the in the β-
myosin heavy chain (β-MyHC; Moore et al., 2012) revealing allelic
genetic heterogeneity. FHC-related mutations, however, were also
found in a large number of other sarcomeric proteins (non-allelic
genetic heterogeneity in FHC), few even in non-sarcomeric pro-
teins. Mutations in the β-MyHC, cardiac myosin-binding protein
C (cMyBPC), cardiac troponin-T (cTnT), and cardiac troponin-I
(cTnI) account for nearly 90% of all FHC-cases. About 40% of
all genotyped FHC-patients carry missense mutations in MYH7,
about 30–40% in the cMyBPC gene (Richard et al., 2003; Fokstuen
et al., 2008; Ho et al., 2010). So far, however, it is still unclear how
altogether several hundred different mutations in a large number
of different sarcomeric and some non-sarcomeric proteins result
in the characteristic features of FHC.
Since FHC is a monogenic disease, the phenotype is thought
to result from the triggering of phenotype development by the
respective mutation (Ashrafian et al., 2011). This raised the ques-
tion about the trigger common to all the different mutations in
the different proteins. In vitro motility and ATPase-assays on iso-
lated sarcomeric proteins together with the analysis of mouse
models led to the hypothesis that enhanced calcium-sensitivity,
increased maximal force generation, and higher ATPase activity
are the common features of FHC-related mutations (Robinson
et al., 2002, 2007; Debold et al., 2007), resulting in impaired
energy metabolism (Spindler et al., 1998; Blair et al., 2001) and
altered calcium-handling in cardiomyocytes (Baudenbacher et al.,
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2008; Guinto et al., 2009). Several data reported about functional
effects of FHC-mutations are in conflict with this hypothesis. For
example, force generation of cardiomyocytes from tissue samples
of affected patients was reduced compared to control for β-MyHC
mutations, mutations in the cMyBPC, and for FHC-patients with
unidentified mutations (Hoskins et al., 2010; van Dijk et al., 2012;
Kraft et al., 2013). For several β-MyHC mutations calcium sensi-
tivity was found reduced, or unchanged but with residual active
forces under relaxing conditions (Kirschner et al., 2005; Kraft
et al., 2013). For only two out of four β-MyHCmutations ATPase
was enhanced but unchanged for the others (Seebohm et al., 2009;
Witjas-Paalberends et al., 2014) while two out of three β-MyHC
mutations showed higher force generation than controls while
force generation was unchanged for the third when force genera-
tion was studied in M. soleus fibers of affected patients (Seebohm
et al., 2009). Thus, the effects of quite many FHC-mutations do
not fall into the previously proposed common mechanism for
FHC-development of increased contractile functions. This could,
in part, be due to secondary effects like myofibrillar disarray
affecting some of these parameters, e.g., maximum force gener-
ation (Kraft et al., 2013). Thus, altogether no common trigger for
FHC-development has been identified so far. Knowing the trigger
and subsequent steps in the pathogenesis of FHC holds the poten-
tial to identify novel targets for novel therapeutic strategies, e.g.,
in the prevention cardiac remodeling in FHC-patients harboring
different FHC-related mutations.
Here we summarize our work on the functional characteriza-
tion of FHC-related mutations in the β-MyHC both in skeletal
and myocardial tissue samples of affected patients. Our goal was
to identify features that might be common to many if not all
FHC-related mutations and thus may be a trigger for develop-
ment of the typical FHC-phenotype by different mutations in
different sarcomeric and even non-sarcomeric proteins. We will
finally discuss a possibly common feature and how it might ini-
tiate myocyte disarray, interstitial fibrosis and hypertrophy, the
hallmarks of FHC-related cardiac remodeling.
EFFECTS OF FHC-RELATED MUTATIONS IN THE β-MyHC ON
FORCE GENERATION AND FIBER STIFFNESS
MEASUREMENTS ON ISOLATED FIBERS OFM. SOLEUS TISSUE
SAMPLES OF FHC-PATIENTS
We had focussed our earlier work on the functional effects of
missense mutations in the converter domain of the β-MyHC,
mutations R719W, R723G, and I736T (cf. Figure 1, Rayment
et al., 1993). Our goal was to identify direct functional effects of
these mutations on muscle function that may be common to all
three mutations and common to other FHC-related mutations,
including mutations in other proteins.
Tissue samples of M. soleus were obtained by open biopsy.
The samples were immediately separated in small bundles and
fiber membranes were dissolved by incubation in skinning solu-
tion, an ATP-containing solution mimicking the intracellular
ionic milieu to which 0.5% Triton X100 was added. Fiber bun-
dles were then equilibrated with solutions containing increasing
concentrations of sucrose (maximum 2M) as a cryoprotectant.
Fiber bundles were then rapidly frozen in liquid propane and
stored in liquid nitrogen until use. For details see Kraft et al.
FIGURE 1 | Structural model of the myosin head domain (Rayment
et al., 1993) illustrating the locations of the converter mutations
R719W, R723G, and I736T. Note location of mutations R719W and R723G
more in the core of the converter in a helix close to the long α-helix of the
light chain binding domain that is anchored in the converter. Mutation I736T
is near the surface of the converter (figure prepared with RasMol).
(1995). For experiments fiber bundles were thawed, individual
fibers were isolated and mounted between a strain gage force
transducer and a motor to control muscle length or load. As
a direct measure of length and length changes of the muscle
fibers we measured sarcomere length by laser light diffraction.
For further details see Seebohm et al. (2009). The mounted indi-
vidual fibers were bathed in different experimental solutions that
mimicked the ionic composition of the intracellular medium.
Different free Ca++-ion concentrations were obtained by adding
the calcium chelator EGTA and CaEGTA in appropriate propor-
tions. Free Ca++-ion concentrations were calculated according
to Föhr et al. (1993). For measurements under rigor conditions,
fibers were incubated in solutions without MgATP that contained
3mM EDTA to quickly remove free Mg++-ions.
We first measured stiffness of single M. soleus muscle
fibers in rigor (Figures 2A,B) and during active contraction
(Figures 2C,D, Seebohm et al., 2009). Stiffness was mea-
sured by applying small ramp-shaped length changes, stretches
(Figure 2A) or releases (Figure 2C) for stiffness in rigor or dur-
ing active contraction, respectively. During these length changes
force and change in sarcomere length were recorded. Fiber stiff-
ness was measured as the slope when force was plotted vs. change
in sarcomere length (cf. Figures 2A,C). For stiffness during active
contraction the slope over the initial 2–3 nm of length change was
determined (red line in Figure 2C) for further details of stiffness
measurements see Brenner (1998). Under rigor conditions and
during active contraction we observed an increased fiber stiffness
for mutations R723G and R719W, while stiffness of fibers with
mutation I736T was unchanged (Figures 2B,C). The increased
stiffness in rigor, i.e., when all myosin heads are attached to actin,
immediately suggested that mutations R723G and R719W both
increase the stiffness of the myosin head domain.
QUANTITATIVE ESTIMATE OF THE CHANGE IN MYOSIN HEAD
STIFFNESS BY MUTATIONS R719W AND R723G
For a quantitative estimate of the increase in stiffness per myosin
head we had to determine the elastic distortion of the myosin
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FIGURE 2 | Effects of mutations R719W, R723G, and I736T on stiffness of
soleus muscle fibers in rigor (absence of nucleotide) and during active
contraction. (A) Principle of stiffness measurement in rigor. In rigor fibers
generate no force when put in rigor by rapid removal of free Mg2+-ions
together with removal of ATP (Brenner et al., 1986). Thus, stiffness was
measured by applying a ramp-shaped stretch (see inset for a schematic
illustration). Stiffness is the slope when force change is plotted vs. applied
change in sarcomere length, measured in nm/half sarcomere (nm/HS). Note
that only the dark part of the traces in the inset are included in the force vs.
length change plot. Noise of this plot was reduced by signal-averaging
responses of several such maneuvers. (B) Fiber stiffness in rigor for the
mutations and control fibers. Speed of stretch ∼3–5 × 103 (nm/half
sarcomere)s−1; T = 5◦C; n = 5–10 fibers. Mean values ± SE, normalized
control fibers, respectively. ∗Difference to controls statistically significant,
p ≤ 0.05. (C) Principle of stiffness measurements during isometric steady
state contraction. When fibers have reached constant isometric force a ramp
shaped release is imposed on the fiber length. This results in a drop of
isometric force (cf. inset for schematic illustration of length change and force
response). Over the initial 2–3 nm of length change the plot of force vs.
sarcomere length change is linear. Deviation from the linear response later in
the release is due to rapid re-equilibration of myosin heads in their different
(Continued)
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FIGURE 2 | Continued
force-generating states. The slope of the initial linear part is determined by
linear regression (red line) and taken as active fiber stiffness. The intercept of
this line with the abscissa is the y0-value. This is interpreted as the elastic
extension of the actin and myosin filaments plus elastic distortion of the force
generating myosin heads (Linari et al., 2007). The plot of force vs. length
change is noisier than in (B). This is due to the fact that fewer measurements
were signal-averaged than under rigor conditions shown in (A). (D) Fiber
stiffness determined during isometric steady state contraction [speed of
release ∼2–4 × 103 (nm/half-sarcomere)s−1]; T = 10◦C to ensure structural
integrity of fibers and stability of striation pattern throughout experiments;
n = 6–14 fibers. Mean values ± SE, normalized control fibers, respectively.
∗Difference to controls statistically significant, p ≤ 0.05. (E) Plot of y0, vs.
isometric force at different levels of calcium-activation. The y0-values were
measured from T-plots (cf. C) at pCa values from 4.5 to 6.6; T = 10◦C. Speed
of length release 4–5 × 103 (nm/half-sarcomere)s−1. Continuous line obtained
by linear regression. Y-axis intercept of solid line is 5.67 nm/HS (HS = half
sarcomere) equals elastic extension of force generating heads (cf. double
headed arrow). Slope of solid line is filament compliance per half-sarcomere,
about 0.025 nm/kPa. Elastic extension of myofilaments at an isometric force
of 120 kPa is illustrated by double arrow. Panels (B, D and E) reprinted with
modifications from Seebohm et al. (2009) with permission from Elsevier.
head vs. elastic extension of myofilaments while active force was
generated or while fibers were in rigor. This was possible from
measurements of active force and active stiffness at different
degrees of Ca++-activation (cf. Linari et al., 2007). Figure 2E
shows these data and illustrates the separation between elastic
head distortion and elastic filament extension at different lev-
els of active force. The slope of the solid line in Figure 2E is
the compliance of the myofilaments. The intercept of this line
with the ordinate at about 5.5 nm/HS represents the elastic exten-
sion of the force-generating cross bridges. This is assumed to be
the same for all levels of Ca++-activation. The y0-value is the
amplitude of fiber release per half-sarcomere that is necessary
to drop active force to zero if no fast redistribution of cross-
bridges among their different states had occurred (intercept of
red solid line in Figure 2C with abscissa at about 8.6 nm/HS).
In this concept the y0 equals the elastic extension/distortion of
the force generating cross-bridges, about 5.6 nm, plus the elas-
tic extension of the myofilaments that increases with the forces
(isometric force) that act on the myofilaments (cf. Linari et al.,
2007).
For a quantitative estimate of the changes in stiffness and in
the contribution to force generation by the individual myosin
head, caused by the converter mutations, we also had to know
how many myosin molecules actually carry the FHC-mutation.
From the autosomal dominant inheritance onemay have assumed
that 50% of the myosin molecules carry the mutation while the
other 50% have the wildtype sequence. Analysis by mass spec-
trometry, however, revealed that the abundance of mutant protein
is not equal to 50% but instead is characteristic for each par-
ticular mutation (allelic imbalance; Figure 3, black bars). The
same allelic imbalance is found for different members of the
same family (cf. I734T, R723G) and for different generations (cf.
R723G), but also in unrelated families with the same mutation
(cf. V606M, R723G). In addition, the same abundance is found in
M. soleus fibers and in left ventricular myocardium (cf. R723G).
Analysis of expression of the mutant allele at the mRNA-level
revealed very similar fractions of mutant mRNA (allelic imbal-
ance) as was found for the mutant protein (Figure 3, gray bars vs.
black bars).
The known fraction of mutant myosin in our samples
allowed us to estimate the change in head stiffness (change
in resistance to elastic distortion) from the observed increase
in fiber stiffness, i.e., of the mixture of mutant and wild-
type myosin molecules, and the known compliance of the
myofilaments (Figure 2C, Seebohm et al., 2009). This estimate
yielded an about 2.6-fold increase in head stiffness for muta-
tion R719W and about 2.9-fold increase for mutation R723G
while mutation I736T had no such effect (Seebohm et al.,
2009).
Based on the fundamental mechanism of force generation, i.e.,
that active forces result from elastic distortion of actin attached
myosin heads caused by structural changes in the myosin head
during its working stroke (Huxley, 1957), an increased head
stiffness that corresponds to an increased resistance to elastic dis-
tortion is expected to result in increased generation of active force.
In fact the estimated increase in stiffness of the individual head
domain indicated by our stiffness measurements predicted an
increase in force generation that was very close to that observed
experimentally, about 2-fold for the head domains with mutation
R723G or R719W (Seebohm et al., 2009).
The increased head stiffness by converter mutations R719W
and R723G implies that the converter domain itself is a major
determinant of head stiffness since a point mutation in a partic-
ular domain can result in an increase in head stiffness only if the
affected domain is a compliant part of the molecule. Stiffening
of an already rigid component would not affect overall “stiff-
ness” of a molecule since overall stiffness is limited by the most
compliant element(s) of the molecule. But why should increased
head stiffness and increased contribution to force generation by
an individual myosin head cause disease?
Since mutations R719W and R723G increased myosin head
stiffness while mutation I736T did not, we wondered whether the
first two mutations were located at particular points in the con-
verter sequence. We therefore compared the amino acid sequence
of the β-cardiac myosin heavy chain (which is also the heavy chain
of slow skeletal muscle) with the sequences of fast skeletal myosin
heavy chains. This revealed that the FHC-mutations R719W and
R723G are located at positions where the β-cardiac/slow MHC
differs from fast MyHC isoforms in the otherwise highly con-
served converter region (cf. Table 1). This raised the question,
whether fast and slow skeletal myosins may actually differ in the
head stiffness and thus the force generated by a cross-bridge in
a force-generating state. We tested this by both stiffness mea-
surements on skinned fibers of human soleus (β-cardiac/slow
skeletal MyHC) vs. rabbit psoas (fast skeletal MyHC-2D) and by
optical trapping on β-cardiac/slow skeletal myosin subfragment
1 prepared from human and rabbit slow skeletal muscle fibers
vs. fast myosin subfragment 1 from the rabbit psoas (Seebohm
et al., 2009; Brenner et al., 2012). This revealed that the fast
MyHC has ≥3-fold higher head stiffness than the slow/β-cardiac
Frontiers in Physiology | Striated Muscle Physiology October 2014 | Volume 5 | Article 392 | 4
Brenner et al. Pathogenesis of familial hypertrophic cardiomyopathy
FIGURE 3 | Fractions of mutated β-cardiac/slow skeletal MyHC-mRNA
and of β-cardiac/slow skeletal MyHC protein for different FHC-mutations.
Gray bars, fractions of mutated mRNA; black bars, fractions of mutated
protein. Data for M. soleus samples of mutations V606M, G584R, I736T,
R719W, and R723G. For mutation R723G data from ventricular myocardium
are also included (LV, left ventricle; RV, right ventricle). Note that all mutations
significantly deviate from equal abundance of wild-type and mutated transcript
(allelic imbalance) with very similar deviations also at the protein level. Allelic
imbalance for mutated mRNA and protein were very similar in M. soleus and
myocardium (mutation R723G). Also note the essentially identical expression
of mRNA and protein both within families (I736T, R723G) and among unrelated
families (V606M, R723G). Reprinted from Tripathi et al. (2011).
Table 1 | Converter sequences and stiffness per myosin head for β-cardiac/slow skeletal and fast skeletal myosin heavy chain isoforms.
719 723 736
  
FPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLL β-cardiac/slow skeletal MyHC I
FPSRILYADFKQRYKVLNASAIPEGQFIDSKKASEKLL skeletal MyHC IIA
FPSRILYADFKQRYKVLNASAIPEGQFIDSKKASEKLL skeletal MyHC IIX/IID
MyHC isoform (source) Stiffness/Head References
FIBER STUDIES
β-cardiac/slow skeletal MyHC I (human soleus) 0.3–0.5 pN/nm Seebohm et al., 2009
Fast skeletal MyHC IID (rabbit psoas) 1.7 pN/nm Linari et al., 2007; Brenner et al., 2012
TRAPPING STUDIES
Slow skeletal MyHC I (rabbit, rat) 0.3–0.4 pN/nm Capitanio et al., 2006; Brenner et al., 2012
Fast skeletal MyHC IIA, D (rabbit back muscle, M. psoas) 2–3 pN/nm Lewalle et al., 2008; Brenner et al., 2012
Yellow, fully conserved residues, unmarked, residues where β-cardiac/slow skeletal myosin heavy chain sequence differs from the fast isoforms. Note that mutations
R719W and R723G are located at positions where fast and slow isoforms differ. Mutation I736T is located at a position where fast and slow isoforms are identical.
Stiffness per myosin head domain of fast and slow MyHC derived from stiffness measurements in muscle fibers and by optical trapping on myosin head domains
(myosin subfragment 1) isolated from muscle tissue.
MyHC (cf. Table 1). This was supported by data in the litera-
ture (cf. Table 1; Capitanio et al., 2006; Lewalle et al., 2008). So
increased head stiffness with increased contribution to force gen-
eration appears to be physiological in fast skeletal muscle fibers.
This made it even more puzzling as to why converter mutations
R719W and R723G cause disease. In addition, increased head
stiffness with increased contribution to force generation can-
not act as a common trigger for FHC-development, not even
for myosin mutations since mutation I736T showed no such
effect.
POSSIBLE EFFECTS ON CROSS-BRIDGE CYCLING KINETICS
To test whether (additional) effects on cross-bridge cycling kinet-
ics are common to all three converter mutations and may be the
common trigger of phenotype development, we measured the
rate constant of force redevelopment (kredev) and fiber ATPase
(Seebohm et al., 2009).
Figure 4A shows original records of measurements of the rate
constant of force redevelopment (top panel) together with the
data obtained for the three converter domain mutations (bot-
tom panel). No statistically significant effects were detectable for
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FIGURE 4 | (A) Rate constant of force redevelopment (kredev). Top panel,
original traces, fiber length, and isometric force vs. time; control fiber,
T = 20◦C. Release/restretch protocol to initiate force redevelopment
(Brenner and Eisenberg, 1986). kredev is the rate constant for the time course
of force redevelopment to the isometric steady state, assuming a single
exponential function. Isometric force is difference between force in isometric
steady state and force level during the period of unloaded shortening where
force has dropped to zero. Bottom panel, kredev observed for mutations
R719W, R723G, and I736T, normalized to kredev of controls; n = 7–45 fibers.
Mean values ± SE. No statistically significant effects could be observed.
(B) Top panel, fiber ATPase, pen recorder trace of change in
NADH-concentration while a single M. soleus fiber was incubated in the
ATPase chamber. At downwards pointing arrow fiber was moved from trough
with preactivating solution into ATPase chamber, at upwards pointing arrow
fiber was moved back to preactivating solution. Maximum calcium activation,
T = 20◦C. ATPase is determined by the NADH-coupled enzyme assay in
which rephosphorylation of ADP by phosphoenol pyruvate is coupled to
reduction of pyruvate to lactate by NADH. Change in NADH concentration is
followed by absorbance at 360 nm, calibrated with NADH test solutions.
Bottom panel, effects of mutations R719W, R723G, and I736T, on fiber
ATPase during isometric contraction (n = 6–21 fibers). T = 20◦C. Mean
values ± SE normalized to ATPase of control fibers. ATPase activity is
significantly affected only by mutation R719W, indicated by ∗p < 0.001
(reprinted from Seebohm et al., 2009 with permission from Elsevier).
all three mutations. Figure 4B shows an original record of fiber
ATPase measurements (top panel). These measurements revealed
a statistically significant increase in ATPase for mutation R719W
by about 20%. These ATPase measurements together with the
unchanged rate constant of force redevelopment suggested some
changes in cross-bridge cycling kinetics for the R719W muta-
tion. A quantitative estimate, however, showed that the changes
in cross-bridge cycling kinetics alone could at most account for
about 1/3 of the increased active force by the resulting higher
occupancy of force generating cross-bridge states during iso-
metric steady state contraction and required the increased head
stiffness to account for the overall increase in active force seen
with mutation R719W. The increased stiffness in rigor, however,
could not at all be accounted for by these changes in cross-bridge
turnover kinetics (Seebohm et al., 2009).
To identify possible effects of the three converter mutations
on cross-bridge kinetics under isotonic conditions we deter-
mined unloaded shortening velocity and force velocity relations
on fibers from M. soleus samples of affected patients. Unloaded
shortening velocity was determined by the slack-test experiment
(Figure 5, top panel; cf. Edman, 1979). As we had previously
shown, the time to shorten a preset distance (imposed fiber slack)
vs. slack amplitude is not a linear relation as expected for a
constant shortening velocity. Instead shortening velocity slows
down with distance of shortening (Brenner, 1986). When the nat-
ural logarithm of velocity, however, was plotted vs. sarcomere
length a linear relation was observed from which the shorten-
ing velocity at the very beginning of unloaded shortening could
be determined (cf. Brenner, 1986). Data of unloaded shortening
velocity determined from fibers of affected patients are shown in
Figure 5 (bottom panel). Only fibers from one patient showed an
increase in unloaded shortening velocity just above the signifi-
cance cut-off of p < 0.05. All other data were not different from
controls.
To test whether our FHC-mutations also significantly reduce
maximum power under loaded shortening, as previously found
for other FHC-mutations (Lankford et al., 1995), we determined
isotonic shortening velocity under different loads for controls and
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FIGURE 5 | Effect of converter mutations on maximum unloaded
shortening velocity (vmax). Top panel: sample traces of slack test
experiment, length vs. time and force vs. time (cf. Edman, 1979). This
illustrates the reconstruction of 4 points of unloaded shortening vs. time
from the time required for unloaded shortening to take up the imposed
slack, i.e., until force starts to redevelop; vmax defined as initial slope of the
shortening curve is determined by curve fitting according to Brenner (1986).
Control fiber at 20◦C. Bottom panel, vmax for mutations R719W, R723G,
and I736T normalized to control fibers; n = 6–11 fibers. T = 20◦C; mean
values ± SE. ∗ indicates statistically significant difference to controls
(p ≤ 0.05). Reprinted from Seebohm et al. (2009) with permission from
Elsevier.
mutations R723G and I736T. For this test, quick releases from
isometric steady state contraction to shortening under load con-
ditions were applied (Figure 6A). Initial shortening velocity at
the different loads was determined by curve fitting according to
Brenner (1986) just as done for unloaded shortening velocity.
The velocity data were plotted vs. applied load (Figure 6B) and
the Hill equation was fitted to the data points (Figure 6B solid
line) to obtain the force-velocity relations. From the Hill equation
we determined the power at different loads (Figure 6C) to deter-
mine whether the convertermutations affect themaximumpower
under isotonic conditions. As shown in Figure 6D, converter
mutations R723G and I736T had no significant effect on max-
imum power under isotonic conditions. For mutation R719W
force velocity relations could not be determined because of insuf-
ficient size of the biopsy to perform all different experiments.
Nevertheless, neither unloaded shortening velocity nor the max-
imum power output could serve as parameters in which all three
converter mutations consistently differ from controls.
FORCE GENERATION AT DIFFERENT DEGREES OF
Ca++-ACTIVATION; Ca++-SENSITIVITY
It was previously reported that FHC-related mutations cause
an increased Ca++-sensitivity of the contractile apparatus
(Robinson et al., 2002; Ashrafian et al., 2011; Marston, 2011). We
therefore measured active force-generation at different degrees
of Ca++-activation and constructed the force-pCa relations. To
exclude effects of different phosphorylation levels of the regula-
tory light chain of myosin (LC2S or MLC-2 fast; Sweeney et al.,
1993) all fibers were dephosphorylated with protein phosphatase
1α (Kirschner et al., 2005). The recorded force-pCa relations are
shown in Figure 7. Somewhat surprisingly we found for converter
mutations R719W and R723G a reduced Ca++-sensitivity. For
mutation I736T Ca++-sensitivity was essentially unchanged but
we found residual active force generation even under relaxing
conditions (Kirschner et al., 2005).
IMPLICATIONS OF THE FUNCTIONAL EFFECTS OBSERVED WITH THE
THREE CONVERTER MUTATIONS
Converter mutations R719W and R723G, both located in the core
of the converter at positions where slow and fast myosins dif-
fer in amino acid sequence, increase head stiffness. This implies
that the converter is a main determinant of head stiffness and
thus of the contribution of a myosin head to force generation.
Mutation I736T, located at the surface of the converter has no
such effect. The other surprising effect is that both R719W and
R723G, opposite to the expectation for FHC-related mutations
(Marston, 2011) reduce Ca++-sensitivity while mutation I736T
has no effect on Ca++-sensitivity but causes an incomplete relax-
ation. In addition, mutation R719W showed some changes in
cross-bridge cycling kinetics. Altogether, up to this point, the
three converter mutations did not show a common direct func-
tional effect. Thus, whilst increased head stiffness is a direct
functional effect of the FHC-mutations R723G and R719W, the
FHC-phenotype cannot simply be the result of increased head
stiffness. Interestingly, higher head stiffness is in fact normal
for fast skeletal muscle myosin when compared with the slow
skeletal isoform (Table 1). So how does increased head stiff-
ness in the β-myosin heavy chain (β-MyHC) cause disease in
myocardium?
HOWMAY MUTATIONS IN THE MYOSIN HEAD DOMAIN TRIGGER
DEVELOPMENT OF AN FHC-PHENOTYPE?
A possible insight into the puzzle of how FHC-related muta-
tions in the myosin head domain with different direct func-
tional effects may cause development of an FHC-phenotype was
revealed when we compared force-Ca++-relationships of indi-
vidual M. soleus fibers of FHC patients. To our surprise, in
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FIGURE 6 | Force-velocity relation and maximum power output.
(A) Original length and force traces of a quick release experiment in which
the fiber was switched from isometric steady state to isotonic shortening.
Load during isotonic shortening about 10% of isometric force. Note the
curved time course of fiber length similar to the time course of unloaded
shortening by the slack test experiment (Figure 5, top panel). Initial
shortening velocity determined according to Brenner (1986).
(B) Force-velocity relation constructed by plotting initial shortening velocity
vs. applied load, i.e., force exerted by fiber during shortening. Solid line is
fit of Hill equation (Hill, 1938) to data points. (C) Power at different loads,
solid line derived from Hill equation fitted to data points, i.e., solid line in
(B). (D) Effect of mutations R723G and I736T on maximum power;
mean ± SE, n = 12 − 14 fibers. Differences not statistically significant
(p > 0.05). T = 20◦C.
some fibers the force-pCa relations were just like those in unaf-
fected controls while other fibers showed substantially different
force-pCa relations (cf. Figure 8, Kirschner et al., 2005).
For mutation R719W force-pCa relations of some fibers
were shifted substantially further to the right than expected
from the “average” fiber (Figure 8 vs. Figure 7A). Similarly,
some fibers with mutation R723G were also shifted much fur-
ther to lower Ca++-sensitivity than the average fiber (Figure 8
vs. Figure 7B). Some fibers with mutation I736T showed sub-
stantially increased forces at partial activation and had still
substantial active forces even at relaxing Ca++-concentrations,
i.e., showed incomplete relaxation while other fibers of the
same tissue sample had force-pCa relations indistinguishable
from control fibers. The common feature of all three FHC-
mutations, however, is the spectrum of force-pCa relations rang-
ing from normal (control) to substantially shifted to “abnormal”
Ca++-sensitivity or enhanced partial activation with incomplete
relaxation.
The relevance of such spectrum of different Ca++-sensitivities
for fibers of the same tissue sample of an individual patient
becomes most obvious when considering force generation at
partial activation. At Ca++-concentrations resulting in control
fibers in about 60% of full activation, e.g., pCa 6.1, the observed
active force generated by individual control fibers varies between
about 50% and 70% of full activation. Thus, in control fibers the
highest observed force levels observed at pCa 6.1 (70% of full
activation; Figure 8) are about 1.5 times higher than the low-
est (50% of full activation). At the same pCa value, about 6.1,
for mutations R719W and R723G the highest forces of indi-
vidual fibers in Figure 8 are at least 4- to 5-fold larger than
the lowest. For mutation I736T the difference between fibers
with highest forces vs. fibers with lowest forces at pCa 6.1
are again in this range (Figure 8). In addition, for mutation
I736T some fibers still generated substantial forces at relax-
ing Ca++-concentrations where control fibers were fully relaxed
(pCa 8.0).
Thus, the common feature for all three FHC-related mutations
in the converter is the much larger spectrum of forces generated
by individual fibers of one and the same patient at partial acti-
vation levels. In skeletal muscle such different force generation
among individual fibers at partial activation means that individ-
ual fibers contribute differently to the force generated by a whole
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FIGURE 7 | Force-pCa relations of converter mutations vs. controls.
N = 19 control fibers. pCa50 of controls, 6.12 ± 0.02. (A) Mutation R719W;
n = 16 fibers; ∗∗ mark data at which difference in active forces are highly
significant (p < 0.001); pCa50 of fibers with mutation R719W, 5.90 ± 0.03,
significantly different from control (p < 0.001) (B) Mutation R723G, n = 13
fibers; pCa50 5.98 ± 0.03, significantly different from control (p < 0.001).
(C) Mutation I736T; n = 10 fibers; ∗ mark data for which difference in force
generation is significant (p < 0.01); pCa50 of fibers with mutation I736T,
6.15 ± 0.04, not significantly different from control (p > 0.05). Note,
however, the incomplete relaxation even at pCa 8. All data recorded after
treatment of fibers with PP1α; modified from Kirschner et al. (2005). With
permission of The American Physiological Society.
muscle. Yet, “stronger” or “weaker” fibers are not expected to
interfere with each others function. This is because skeletal mus-
cle fibers do not form cellular networks but contribute to total
force of a muscle independently.
WHAT MAY BE THE REASON FOR THE VARIANCE FROM NORMAL TO
MUCH ALTERED Ca++-SENSITIVITY AMONG INDIVIDUAL FIBERS OF
THE SAME FHC-PATIENT?
We had previously observed that in soleus muscle samples
of FHC-patients mutant and wildtype β-cardiac/slow skeletal
MyHC were not expressed equally, different to what one may
have expected for heterozygous patients with an autosomal dom-
inant disease. Instead each mutation has a characteristic fraction
of mutant β-cardiac/slow skeletal MyHC both at the mRNA and
protein level (Figure 3, Tripathi et al., 2011). We therefore won-
dered whether the fraction of β-cardiac/slow skeletal MyHC may
also vary from fiber to fiber. Because of the very small amount
of material obtainable from individual soleus fiber segments we
could only determine the fraction of mutant β-cardiac/slow skele-
tal MyHC at the mRNA level. Individual M. soleus fibers of a
patient with mutation R723G showed quite different fractions
of mutant mRNA, ranging from about 10% to essentially 100%
(Figure 9). The high number of fibers with almost 100% mutant
mRNA is consistent with the observation that in soleus samples
(tissue level) the average fraction of mutated mRNA is ≥2/3 of
total β-cardiac/slow skeletal MyHC-mRNA (cf. Figure 3).
In tissue samples of FHC-patients we always found a close
correlation between fraction of mutant mRNA and fraction of
mutant protein, regardless of the FHC-mutation we studied
(Figure 3, Tripathi et al., 2011). Thus, the observed large vari-
ation in the fraction of mutant mRNA among individual fibers
of soleus muscle of affected patients very likely correlates with
a similar variation in the fraction of mutant protein. The large
variation in mutant mRNA and thus in mutant protein among
individual soleus fibers of affected patients could well account for
the large functional variation among individual fibers, as judged
by the force-pCa relations and the large variation in active force
at partial activation (cf. Figure 8, Kirschner et al., 2005).
Assuming that the fibers with the largest shift in force-pCa
relations have the highest abundance of mutant β-cardiac/slow
skeletal MyHC, e.g., 100% as the maximum, forces generated by
these fibers would at most be 2-fold larger than force of control
fibers. This is because force generation per head with mutations
R719W or R723G was estimated to be about 2-fold higher than
force generation by wildtype myosin heads; see above (Kirschner
et al., 2005). As a consequence, the forces at partial activation
(pCa ≥ 6.3), as low as 1/5 of control fibers in the normalized
plots (Figure 8), would still be less than half of control in abso-
lute terms. At pCa around 5.8–5.9 fibers with mutant myosin are
expected to generate about the same amount of absolute force as
controls, at higher activation levels fibers with mutations R719W
or R723G would generate higher forces than controls, reaching
up to 2-fold higher forces at maximum activation for fibers with
100% mutant myosin. Most importantly, however, even if abso-
lute forces of individual fibers are considered, the large variation
in Ca++-sensitivity among individual fibers remains unaffected.
IN MYOCARDIUM DIRECT FUNCTIONAL EFFECTS CAN BE MASKED OR
EVEN REVERSED BY SECONDARY EFFECTS
Characterization of functional effects of FHC-related mutations
in myocardium for comparison with the effects seen in M. soleus
fibers became possible by samples from explanted hearts of
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FIGURE 8 | Force-pCa relations of individual M. soleus fibers. Controls, 10
fibers of a control individual; R719W, 16 fibers (cf. Figure 7A); R723G, 13 fibers
(cf. Figure 7B); I736T, 25 individual fibers. Heavy solid lines in plots of fibers
with mutations represent the average force-pCa relation of the control fibers.
Note that for all three mutations the individual force-pCa relations represent a
continuum from relations like control fibers to force-pCa relations substantially
shifted beyond the average position of the corresponding mutation shown in
Figure 7, i.e., to the right for mutations R719W and R723G, and upwards to
incomplete relaxation for mutation I736T. Modified from Kirschner et al.
(2005). With permission of The American Physiological Society.
patients with the myosin missense mutations, R723G, one of the
mutations that we had studied on soleus muscle samples.
Cardiomyocytes were mechanically isolated from the flash-
frozen tissue samples (van der Velden et al., 2003; Kraft et al.,
2013). After chemical permeabilization the isolated cardiomy-
ocytes were attached to a force transducer and motor such that
active and passive forces and kinetics of cross-bridge cycling
(kredev) could be measured at different concentrations of free
Ca++-ions. To our surprise, force-pCa relations of cardiomy-
ocytes isolated from the flash-frozen samples of explanted
myocardium of two patients with mutation R723G showed (i) no
difference in Ca++-sensitivity and (ii) reduced maximum active
force compared to myocytes from donor hearts (Figure 10A).
This was in total contrast to the reduced Ca++-sensitivity and
increased maximum force seen in soleus samples with the same
mutation.
Analysis of phosphorylation of contractile proteins revealed
substantially lower phosphorylation of troponin I in these
myocardial samples with mutations compared to the controls.
When the phosphorylation pattern was matched with controls by
treatment with protein kinase A (PKA) or by a combination of
dephosphorylation by protein phosphatase-1α (PP-1α) followed
by phosphorylation with PKA, the mutant samples showed a sim-
ilarly reduced Ca++-sensitivity as the soleus fibers of patients
with the R723G-mutation (Figure 10A vs. Figure 10B).
Maximum force, however, was still substantially reduced
after matching phosphorylation of patient samples with con-
trols (Figure 10B, left panel). An explanation for the reduced
force generation in myocardium in contrast to the increased
force generation in soleus fibers with the same mutation was
revealed by electron microscopy of tissue samples of affected
patients. In myocardium of affected patients prominent intra-
cellular myofibrillar disarray and reduced packing of myofibrils
within cardiomyocytes was observed with non-myofibrillar and
non-mitochondrial material taking up substantial intracellular
volume (Kraft et al., 2013). Quantitatively, myofibrillar density
of cardiomyocytes of affected patients with mutation R723G
was reduced by about 26%. Without such reduced myofibril-
lar density within cardiomyocytes, force generation per cross-
sectional area had been essentially the same as in control samples
(Kraft et al., 2013). The additional myofibrillar disarray with
myofibrils deviating from the longitudinal axis of a cardiomy-
ocyte will add to reduced force generation in axial direction
(Friedrich et al., 2010) such that increased force generation is
not observed even when accounting for reduced myofibrillar
density.
Altogether, the opportunity to compare effects of the R723G
missense mutation in both soleus fibers and myocardium of
affected patients revealed that at least at stages of disease develop-
ment when myectomies were taken or when transplantation was
necessary, direct functional effects of FHC-related mutations can
be masked or even reversed by effects most likely subsequent to
the direct functional effects. This suggests that e.g., FHC-typical
cardiomyocyte and myofibrillar disarray are not direct results of
FHC-related mutations but develop subsequently as a result of
functional alterations. Functional effects of different mutations
apparently converge to a common path of changes resulting in the
FHC-phenotype. Cardiomyocyte and myofibrillar disarray may
represent the start of this common path leading to e.g., interstitial
fibrosis and hypertrophy.
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FIGURE 9 | Fraction of mutated β-cardiac/slow skeletal MyHC-mRNA
in 11 individual fibers of M. soleus of a patient with mutation R723G. A
fiber bundle of M. soleus, flash-frozen without prior skinning, was freeze
dried for isolation of individual fibers (Stienen et al., 1983) without
cross-contamination of mRNA from fiber to fiber. For quantification of the
fraction of mutated β-cardiac/slow skeletal MyHC-mRNA, isolated
segments (2–3mm) of individual fibers were processed as previously
described for M. soleus fiber bundles (Tripathi et al., 2011). Note the large
variation in the fraction of mutated β-cardiac/slow skeletal MyHC-mRNA
among individual fibers.
So what may be a feature common to different FHC-related
mutations that could trigger cardiomyocyte and myofibrillar dis-
array as the start on a common path to an FHC-phenotype?
HYPOTHESIS FOR DEVELOPMENT OF AN FHC-PHENOTYPE
IN MYOCARDIUM
In our previous work on FHC-related missense mutations in the
β-cardiac/slow skeletal MyHC we made three key observations.
(i) A large variation in calcium sensitivity among individual M.
soleus fibers of FHC-patients with mutations R723G, R719W, and
I736T. This variation ranged from essentially normal calcium sen-
sitivity to highly different, e.g., reduced calcium sensitivity for
mutations R719w and R723G. (ii) The ratio of mutated vs. wild-
type β-cardiac/slow skeletal MyHC is not 1:1 but characteristic
for each mutation. In addition this ratio is very similar at both
the mRNA and protein level. (iii) Among individual fibers of M.
soleus samples with the R723G mutation, the ratio of mutant vs.
wildtype mRNA varies from almost pure mutant to almost pure
wildtype. A substantial variation in the ratio of mutant vs. wild-
type protein from fiber to fiber was previously also found for the
R403Qmutation in the β-cardiac/slow skeletal MyHC (Malinchik
et al., 1997).
Based on these three observations, we proposed the follow-
ing hypothesis for a common trigger of the FHC-phenotype
development (Figure 11, Kirschner et al., 2005; Tripathi et al.,
2011):
(i) Variation of the fraction of the mutated protein among indi-
vidual cardiomyocytes (different gray levels of schematic
cardiomyocytes in Figure 11), just as seen among individual
M. soleus fibers, results in functional imbalances, e.g.,
unequal force generation particularly at low activation levels
(cf. Figure 8) among the individual cardiomyocytes.
(ii) Since cardiomyocytes, different from skeletal muscle fibers,
are branched and form a cellular network (Figure 12A),
such variance in force generation among individual cells will
result in uneven contraction, i.e., over-contraction vs. over-
stretch of cardiomyocytes during each twitch. Such func-
tional imbalance will not only occur during force generation
(pressure development in the ventricles) but also during
shortening under load (ejection period). This is because for
cells generating higher forces the relative load during ejec-
tion period will be lower compared to cells generating lower
forces, even if vmax is unaffected by a mutation. As a result,
over-contraction of some cells while others are overstretched
will distort the myocyte network at the cellular and myofib-
rillar level (Scheme in Figure 12B vs. Figure 12C, and left
panel in Figure 12D vs. right panel).
(iii) The structural disorganization, even if initially only a
transient feature during each twitch, however, will result
in progression of persisting structural disorganization over
months and years because of the triggering of secondary
changes. Structural distortion could, for example, trigger
stretch sensitive signaling, e.g., Tgf-β signaling by cardiomy-
ocytes and non-myocyte-cells (right panel in Figure 12D)
that was shown to be critical for pathologic remodeling of
the myocardium in FHC (Teekakirikul et al., 2010). Stretch
induced increase in Tgf-β was found in cell cultures both for
cardiomyocytes and non-myocyte-cells (Ruwhof et al., 2000;
van Wamel et al., 2001, 2002). In our hypothesis, structural
disorganization of the cellular network of the myocardium
because of functional imbalance among individual car-
diomyocytes initiates, via stretch-sensitive signaling paths,
cardiac remodeling (Figure 12E) with interstitial fibrosis,
cellular disarray and hypertrophy, i.e., hallmarks of the
FHC-phenotype (Ho et al., 2010). Increased collagen
synthesis in a profibrotic myocardial state (Ho et al., 2010),
supports our concept.
Based on this concept, for prevention of FHC-phenotype devel-
opment therapeutic interventions are required that affect myocar-
dial function differentially, e.g., specifically the altered function
of the mutant protein, otherwise the functional imbalance will
not be reduced and cardiac remodeling will not be prevented.
Alternatively, inhibition of subsequent, e.g., stretch-induced sig-
naling that initiates interstitial fibrosis could be a therapeutic
target to prevent fibrosis and cardiac remodeling. This target was
recently addressed by Teekakirikul et al. (2010).
Since skeletal muscle fibers are only very rarely branched, a
similar extensive disarray is not expected and not observed in
M. soleus fibers. Central core disease, found in soleus fibers of
some FHC-patients are localized changes inside the soleus fibers
with absence of mitochondria, smaller myofibrils, some over-
contracted sarcomeres and irregular Z-discs (Fananapazir et al.,
1993). This, however, is different from the extensive disarray seen
in myocardium and may suggest unequal abundance of mutated
protein along skeletal muscle fibers. Overcontracted sarcomeres
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FIGURE 10 | Effect of mutation R723G in myocardium. (A) Isolated
cardiomyocytes, native state of phosphorylation. Left panel, maximum
active force per cross sectional area at saturating calcium-concentration
(Fmax). Fmax of MyHC723-cardiomyocytes (light gray bar) is 35% lower
than Fmax of donor cells (hatched bar; ∗p < 0.05). Right panel, force-pCa
relation normalized to maximum force at saturating Ca++-ion
concentration (pCa 4.5). Solid and dotted lines, fits of a modified Hill
equation yielding pCa50. Note that opposite to M. soleus fibers,
cardiomyocytes isolated from a tissue sample of an explanted heart
show a decrease in maximum active force with no shift in the force-pCa
relation. (B) Isolated cardiomyocytes after incubation with protein kinase
A (PKA) to match phosphorylation of contractile proteins, particularly of
cTnI. Left panel, Fmax after treatment with PKA ∗p < 0.05. Note that
PKA-treatment does not change the difference in Fmax between
R723G-cardiomyocytes and controls. Right panel, force-pCa relations of
MyHC723-cardiomyocytes (gray filled circles, dashed line) vs. donor
cardiomyocytes (gray filled triangles, dashed-dotted line). Note the shift of
the force-pCa relation of MyHC723-cardiomyocytes vs. donor after PKA
treatment. For comparison force-pCa relations obtained before PKA
treatment are also plotted in the same graph (open circles and solid line,
MyHC723-cardiomyocytes; open triangles and dotted line, controls). Lines
are fits of modified Hill equation to data points. Note that after
PKA-treatment to match phosphorylation of e.g., cTnI, a similar reduced
Ca++-sensitivity becomes detectable for MyHC723-cardiomyocytes just
like that seen in the soleus fibers. Modified from Kraft et al. (2013). With
permission of the Journal of Molecular and Cellular Cardiology.
and irregular Z-discs may not be unexpected since skeletal muscle
fibers have multiple nuclei. Thus, variation in the expression of
mutant vs. wildtype mRNA and protein among different nuclei
may exist within skeletal muscle fibers and thus cause functional
imbalances along these fibers.
In our hypothesis, any functional imbalance among individ-
ual cardiomyocytes, resulting from e.g., variable abundance of a
mutant protein, has the potential to induce an FHC-phenotype.
This could include not only missense mutations that affect force
output of cardiomyocytes (poison peptide principle), but also
the expression and degradation of truncated proteins, result-
ing in variable amounts of normal protein (principle of haplo-
insufficiency). In principle, non-sarcomeric proteins that affect
contractile function could also trigger FHC-phenotype develop-
ment if unequal effects are generated among individual cardiomy-
ocytes, e.g., by variation in expression of the mutant protein. In
homozygous patients, found only very rarely, functional imbal-
ance is not expected and the disease is dominated by direct
functional effects of the mutations. These are always present and
lead to the functional imbalance in the heterozygous patients
when mutant protein varies from cell to cell.
TESTING THE HYPOTHESIS
Our hypothesis is based on the assumption that among individual
cardiomyocytes a similar variation in the expression of mutant vs.
wildtype mRNA exists as shown in Figure 9 for M. soleus fibers,
and that this results in functional variation, i.e., imbalances in
force generation and shortening among neighboring cardiomy-
ocytes. Thus, quantification of mutant vs. wildtype mRNA in
individual cardiomyocytes is a critical test for our hypothesis.
First trials of such quantification of mutant vs. wildtype mRNA
in individual cardiomyocytes indicate that indeed the expression
of mutant mRNA varies among individual cardiomyocytes from
near zero to almost pure mutant mRNA (Montag et al., 2014).
IN SUMMARY
Our functional studies on tissue samples of FHC-patients showed
that missense mutations in the myosin head domain do not
Frontiers in Physiology | Striated Muscle Physiology October 2014 | Volume 5 | Article 392 | 12
Brenner et al. Pathogenesis of familial hypertrophic cardiomyopathy
FIGURE 11 | Scheme illustrating the difference between equal
abundance of mutant protein in all cardiomyocytes (top left) vs.
variation in abundance among individual cardiomyocytes (top right).
Gray level illustrates abundance of mutant protein. Unequal abundance of
mutant protein in individual cardiomyocytes results in functional imbalance
that distorts the cellular network of the myocardium (bottom right).
Overstretch vs. overcontraction results in highly variable activation of e.g.,
stress/strain signaling with development of disarray, hypertrophy, and
interstitial fibrosis in the long run.
result in a direct functional effect common to all mutations
like increased force generation, increased Ca++-sensitivity, or
increased ATPase. One feature common to all mutations we
have studied is a large variation in the force-pCa-relation among
individual M. soleus fibers from normal to highly different.
As a consequence, particularly at partial activation large dif-
ferences in the generated active forces exist among individual
fibers. Quantification of mutant mRNA suggests that this func-
tional variation is due to variation in the fraction of mutant
β-cardiac/slow skeletal MyHC present in individual fibers. If such
functional imbalance among individual cells exists in a cellular
network like themyocardium, the functional imbalance will result
in distortions of cells within this network. We hypothesize that
such structural distortions result in myocyte and myofibrillar dis-
array and activate stretch-induced signaling, e.g., Tgf-β-signaling,
that initiates cardiac remodeling with interstitial fibrosis and
hypertrophy, the structural hallmarks of FHC. On this basis, any
mutation in a sarcomeric or non-sarcomeric protein that results
in similar functional imbalance among individual cardiomyocytes
has the potential to trigger development of an FHC-phenotype.
Such a mechanism as the trigger of FHC-development would
have fundamental implications for therapeutic strategies. For
such a pathomechanism either mutation-selective interventions
are needed to ameliorate functional imbalances among indi-
vidual cardiomyocytes to prevent FHC-phenotype development.
Alternatively, inhibition of stretch-induced signaling, e.g., Tgf-β-
signaling could be another target to prevent cardiac remodeling
in FHC.
FIGURE 12 | Expected response of the cellular network of myocardium
to imbalances in force generation among individual cardiomyocytes,
e.g., by mutations R719W or R723G. Orange lines and orange cells
represent extracellular connective tissue and non-myocyte cells within the
myocardium. (A) Confocal image of a longitudinal section through
myocardium (adult mouse). Intercalated discs (vertical lines and
“staircases” labeled with arrow heads) labeled with a mouse monoclonal
antibody to pan Cadherin and an Alexa 488-linked goat-anti-mouse antibody.
Horizontal lines are plasma membranes visualized by staining glycoproteins
containing β-N-acetyl-D-glucosamine with FITC-conjugated wheat germ
agglutinin (for details see Schipke et al., in press). TO-PRO®-3 Iodide used
for staining nuclei (blue). By this approach, individual cardiomyocytes are
delineated. Note that individual cardiomyocytes are not arranged in
independent columns. Instead, cardiomyocytes make contact via
intercalated discs with cardiomyocytes of adjacent columns resulting in a
cellular network. Presumed non-myocyte cells are labeled with white
arrows. (B) Schematic representation of the cellular arrangement in
myocardium with branched cardiomyocytes while relaxed. The darker the
gray-level the higher the abundance of the mutant myosin. The mutation is
assumed to result in substantially lower forces at partial activation levels
despite higher force at maximum activation, as was seen for mutations
R719W and R723G (cf. Figure 8) (C) Same cellular network during
contraction (partial activation like in a twitch). For cardiomyocytes with
mutations R723G or R719W higher abundance of the mutant myosin
(darker gray levels) results in lower forces at partial activation. Thus, during
a twitch these cardiomyocytes become overstretched by those with low
abundance of the mutant protein (lighter gray levels). Due to the branching,
different parts even of individual cells will experience different forces by the
different connections with neighboring cells and will therefore shorten or be
stretched to different extent (see steps in intercalated discs, represented by
dark solid vertical lines separating adjacent cells). Due to relative movement
of cells in parallel strands, branches between the strands will be distorted
as will be the non-myocyte cells in between the strands of cardiomyocytes.
(Continued)
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FIGURE 12 | Continued
(D) Left panel, boxed part of (B) magnified to illustrate striation pattern;
right panel, boxed part of (C). Note the developing differences in sarcomere
lengths of myofibrils during contraction even within an individual cell. This is
due to the branching of the cells and the different forces acting on the
branches due to the unequal force generating capability of adjacent cells by
the different abundance of mutant protein (functional imbalance). Thus,
functional imbalance among individual cardiomyocytes together with the
cellular network of the cardiomyocytes are expected to trigger cellular and
myofibrillar disarray whenever, by variation in expression, a mutation causes
unequal force generation among individual cardiomyocytes during a twitch.
This state would represent the profibrotic state of the myocardium (Ho
et al., 2010) in which stretch triggers increased expression of e.g., Tgf-β (red
spheres) by cardiomyocytes and non-myocyte cells activating development
of interstitial fibrosis. Such distortion will take place during force generation
(pressure development) and will be enhanced during shortening under load
(ejection period). This will occur even if maximum shortening velocity is
unaffected by the mutation because the relative load will be lower for
“strong” cells (low abundance of mutant protein) vs. “weak” cells (high
abundance of mutant protein). Note, that if the mutant protein were
expressed equally in all cells, force generation at any time during a twitch
would be affected equally and no or only minimal changes in the
arrangement of cardiomyocytes would take place during a twitch, i.e., no or
only much smaller changes from the arrangement in (B) would be seen.
Panel (E) illustrates a later stage of phenotype development when e.g.,
stretch-sensitive signaling has triggered development of interstitial fibrosis
with increased cellular disarray. The increase in cell size by signaling paths
that trigger hypertrophy is not shown.
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